PT - JOURNAL ARTICLE AU - Crichton, Megan L. AU - Dudgeon, Emily K. AU - Shoemark, Amelia AU - Chalmers，詹姆斯d·TI -验证的支气管扩张影响测量(BIM)——一本小说病人报告结果衡量援助- 10.1183/13993003.03156 -2020 DP - 2020年1月01 TA -欧洲呼吸杂志PG - 2003156 4100 - 4099 - //www.qdcxjkg.com/content/early/2020/11/11/13993003.03156 2020. -短//www.qdcxjkg.com/content/early/2020/11/11/13993003.03156-2020.full AB -导论支气管扩张试验中使用的现有生活质量和症状工具要么不是疾病特异性的，要么是复杂的，没有一致的反应。我们开发了一个简单的患者报告的视觉模拟结果测量，支气管扩张影响测量(BIM)，用于临床研究，包括临床试验。方法邀请苏格兰东部某三级转诊诊所的支气管扩张患者在基线时填写BIM问卷和支气管扩张生活质量问卷，并在2周和6个月后重复填写问卷。我们通过评估急性发作期间的变化来评估内部一致性、测试重测信度、结构效度和反应性。结果纳入173例患者。8个领域(咳嗽、咳痰、呼吸困难、疲劳、活动、一般健康、控制、恶化)显示出极好的内部一致性(Cronbach α 0.93)。类内相关系数(ICC)在2周内表现出良好的可靠性，包括咳嗽(0.79 (95%CI 0.70-0.85))、痰(0.86 (95%CI 0.80-0.90))、呼吸困难(0.82 (95%CI 0.84 - 0.87))、疲劳(0.88 (95%CI 0.82 - 0.91)、活动(0.84 (95%CI 0.77-0.89)、一般健康(0.81 (95%CI 0.74-0.87))、对照组(0.83 (95%CI(0.75-0.88))和加重期(0.71 (95%CI(0.60-0.79))。结构域与支气管扩张的严重程度和加重史密切相关。 Both distribution and patient-based methods estimated the MCID for each domain as 1.5 points on a 10-point scale. Statistically significant changes in all BIM domains were observed during an acute exacerbation.Conclusion The BIM is a simple patient reported outcome. This study validates the internal consistency, reliability, construct validity and response of the tool at acute exacerbation. Further validation of the tool is now required.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Crichton reports personal fees from AstraZeneca, outside the submitted work.Conflict of interest: Dr. Dudgeon has nothing to disclose.Conflict of interest: Dr. Shoemark has nothing to disclose.Conflict of interest: Dr. Chalmers reports grants and personal fees from Astrazeneca, grants and personal fees from Boehringer Ingelheim, personal fees from Chiesi, grants and personal fees from Glaxosmithkline, grants from Gilead Sciences, grants and personal fees from Insmed, personal fees from Novartis, personal fees from Zambon, outside the submitted work.